Literature DB >> 19380819

The avidity and lytic efficiency of the CTL response to HTLV-1.

Tarek Kattan1, Aidan MacNamara, Aileen G Rowan, Hirohisa Nose, Angelina J Mosley, Yuetsu Tanaka, Graham P Taylor, Becca Asquith, Charles R M Bangham.   

Abstract

In human T-lymphotropic virus type 1 (HTLV-1) infection, a high frequency of HTLV-1-specific CTLs can co-exist stably with a high proviral load and the proviral load is strongly correlated with the risk of HTLV-1-associated inflammatory diseases. These observations led to the hypothesis that HTLV-1 specific CTLs are ineffective in controlling HTLV-1 replication but contribute to the pathogenesis of the inflammatory diseases. But evidence from host and viral immunogenetics and gene expression microarrays suggests that a strong CTL response is associated with a low proviral load and a low risk of HAM/TSP. Here, we quantified the frequency, lytic activity and functional avidity of HTLV-1-specific CD8(+) cells in fresh, unstimulated PBMCs from individuals with natural HTLV-1 infection. The lytic efficiency of the CD8(+) T cell response-the fraction of autologous HTLV-1-expressing cells eliminated per CD8(+) cell per day-was inversely correlated with both the proviral load and the rate of spontaneous proviral expression. The functional avidity of HTLV-1-specific CD8(+) cells was strongly correlated with their lytic efficiency. We conclude that efficient control of HTLV-1 in vivo depends on the CTL lytic efficiency, which depends in turn on CTL avidity of Ag recognition. CTL quality determines the position of virus-host equilibrium in persistent HTLV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19380819     DOI: 10.4049/jimmunol.0900069

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  In vivo modulation of avidity in highly sensitive CD8(+) effector T cells following viral infection.

Authors:  Beth C Holbrook; Rama D Yammani; Lance K Blevins; Martha A Alexander-Miller
Journal:  Viral Immunol       Date:  2013-08-24       Impact factor: 2.257

2.  Changes in functional but not structural avidity during differentiation of CD8+ effector cells in vivo after virus infection.

Authors:  Samuel Amoah; Rama D Yammani; Jason M Grayson; Martha A Alexander-Miller
Journal:  J Immunol       Date:  2012-06-15       Impact factor: 5.422

3.  Lack of recall response to Tax in ATL and HAM/TSP patients but not in asymptomatic carriers of human T-cell leukemia virus type 1.

Authors:  Sharrón L Manuel; Mohit Sehgal; John Connolly; George Makedonas; Zafar K Khan; Jay Gardner; Michael R Betts; Pooja Jain
Journal:  J Clin Immunol       Date:  2013-07-26       Impact factor: 8.317

4.  HTLV-1-infected asymptomatic carriers compared to HAM/TSP patients over-express the apoptosis- and cytotoxicity-related molecules.

Authors:  Asadollah Mohammadi; Bahare Fazeli; Zohreh Poursina; Farahnaz Tehranian; Veda Vakili; Reza Boostani; Houshang Rafatpanah
Journal:  Med Microbiol Immunol       Date:  2019-07-18       Impact factor: 3.402

5.  In vivo immunogenicity of Tax(11-19) epitope in HLA-A2/DTR transgenic mice: implication for dendritic cell-based anti-HTLV-1 vaccine.

Authors:  Divya Sagar; Shet Masih; Todd Schell; Steven Jacobson; Joseph D Comber; Ramila Philip; Brian Wigdahl; Pooja Jain; Zafar K Khan
Journal:  Vaccine       Date:  2014-04-13       Impact factor: 3.641

6.  Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells.

Authors:  Frederic Toulza; Kisato Nosaka; Yuetsu Tanaka; Tiziana Schioppa; Frances Balkwill; Graham P Taylor; Charles R M Bangham
Journal:  J Immunol       Date:  2010-06-04       Impact factor: 5.422

7.  Avidity of influenza-specific memory CD8+ T-cell populations decays over time compromising antiviral immunity.

Authors:  Ian R Humphreys; Mathew Clement; Morgan Marsden; Kristin Ladell; James E McLaren; Kathryn Smart; James P Hindley; Hayley M Bridgeman; Hugo A van den Berg; David A Price; Ann Ager; Linda Wooldridge; Andrew Godkin; Awen M Gallimore
Journal:  Eur J Immunol       Date:  2012-10-16       Impact factor: 5.532

8.  Is There a Role for HTLV-1-Specific CTL in Adult T-Cell Leukemia/Lymphoma?

Authors:  Aileen G Rowan; Charles R M Bangham
Journal:  Leuk Res Treatment       Date:  2011-11-30

9.  Immunopathogenesis of human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: recent perspectives.

Authors:  Mineki Saito; Charles R M Bangham
Journal:  Leuk Res Treatment       Date:  2012-02-06

10.  Genome-wide determinants of proviral targeting, clonal abundance and expression in natural HTLV-1 infection.

Authors:  Anat Melamed; Daniel J Laydon; Nicolas A Gillet; Yuetsu Tanaka; Graham P Taylor; Charles R M Bangham
Journal:  PLoS Pathog       Date:  2013-03-21       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.